Home › Research › Biomarkers
Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease
Peña-Bautista C, Álvarez-Sánchez L, Pascual R, Moreno MJ, Baquero M, Cháfer-Pericás C.. European journal of clinical investigation, 2022-11-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease (AD) is a complex disease that shares clinical features with other dementias. It is important to establish a specific and reliable diagnosis. Nowadays, AD diagnosis is based on cerebrospinal fluid (CSF) biomarkers. However, the corresponding cut-offs differ amongst studies. This study aims to evaluate the CSF biomarkers in the AD differential diagnosis. Methods Clinical relevant biomarkers (amyloid β42 (Aβ42), t-Tau, p-Tau, amyloid β40 (Aβ40), neurofilament light chain (NfL)) were determined in CSF samples from participants classified as AD (n = 124) and non-AD (n = 148) patients from the Neurology Unit. They were included and evaluated consecutively (August 2018-October 2020). The clinical utility of these biomarkers was evaluated by AUC-ROC curves and the corresponding cut-off points were defined. Results The results showed satisfactory accuracy (AUC-ROC 0.91 for Aβ42, 0.890 for t-Tau and 0.933 for p-Tau); whilst Aβ40 and NfL did not show good discriminatory capacity (AUC-ROC 0.557 and 0.738, respectively). The ratios Aβ42/Aβ40 and t-Tau/Aβ42 improved the diagnosis indices of each individual biomarker, with AUC-ROC of 0.980 and 0.971, respectively. Also, elevated levels of NfL were found in the frontotemporal dementia group compared with the other participant groups. Conclusions The ratio Aβ42/Aβ40 showed the highest discriminating capacity between AD and non-AD patients and might be useful in clinical practice. Regarding NfL, it is not a specific biomarker for AD; however, it might be helpful for the differential diagnosis of frontotemporal dementia. Nevertheless, further analysis in an external cohort is required in order to validate these results.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Peña-Bautista, C., Álvarez-Sánchez, L., Pascual, R., Moreno, M. J., Baquero, M., & Cháfer-Pericás, C. (2023). Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease. European journal of clinical investigation. https://doi.org/10.1111/eci.13910
Vancouver
Peña-Bautista C, Álvarez-Sánchez L, Pascual R, Moreno MJ, Baquero M, Cháfer-Pericás C. Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease. European journal of clinical investigation. 2023. doi:10.1111/eci.13910. PMID: 36401799.
BibTeX
@article{penabautista2023-36401799,
author = {Peña-Bautista, C. and Álvarez-Sánchez, L. and Pascual, R. and Moreno, M. J. and Baquero, M. and Cháfer-Pericás, C.},
title = {{Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease}},
journal = {European journal of clinical investigation},
year = {2023},
doi = {10.1111/eci.13910},
pmid = {36401799},
url = {https://doi.org/10.1111/eci.13910}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results The results showed satisfactory accuracy (AUC-ROC 0.91 for Aβ42, 0.890 for t-Tau and 0.933 for p-Tau); whilst Aβ40 and NfL did not show good discriminatory capacity (AUC-ROC 0.557 and 0.738, respectively).
- Also, elevated levels of NfL were found in the frontotemporal dementia group compared with the other participant groups.
- Nevertheless, further analysis in an external cohort is required in order to validate these results.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants124
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of clinical investigation) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 124 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36401799) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “clinical”
7 studies in the library carry the topic tag “clinical”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 7 tagged studies.